Use of romosozumab for osteoporosis in β-thalassemia major
Chrislyn Ng, Navira Samad, Anne Trinh, Frances Milat, Phillip Wong · 2026
Read Use of romosozumab for osteoporosis in β-thalassemia major by Chrislyn Ng, Navira Samad, Anne Trinh, Frances Milat, Phillip Wong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13232785.txt.
Description
Chrislyn Ng and four co-authors report the first use of a bone-building drug in patients whose bones are being eaten by their blood disease, in this 2026 case series. Beta-thalassemia major wrecks skeletons several ways at once: the marrow expands, hormones falter, iron poisons tissue, and bone turnover accelerates. Fractures follow trivial knocks.
Standard care leans on transfusions, iron removal, hormone replacement, and drugs that slow bone loss. Both patients here had severe osteoporosis despite long exposure to those bone-sparing drugs. Twelve months of monthly romosozumab, an antibody that both builds bone and slows its loss, changed the picture: density scans improved significantly in both. Two cases cannot settle efficacy, and the authors claim no more than promise. For a population with few options, promise is worth publishing.
Catalog record
| CREATOR | Chrislyn Ng, Navira Samad, Anne Trinh, Frances Milat, Phillip Wong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |